About
The inventor behind the infrastructure.
PuroGen exists to solve problems that cannot tolerate failure — creating validated systems for environments where certainty is required.
Foundation
Mission
Invent within constraints
We create systems designed for regulation from the first principle, not adapted to compliance afterward.
Approach
Validation as method
Documentation and proof are integrated throughout development, not applied at the end.
Outcome
Inherent correctness
Systems that work because they were invented correctly, not because they were marketed well.
Philosophy
Regulation as creative framework.
Most organizations treat regulatory requirements as constraints to manage. PuroGen treats them as architectural inputs — the specifications that shape what gets invented and how it gets proven. This distinction is foundational. It means every system we produce was designed for its regulatory context, not adapted to it after the fact.
Timeline
1996
Origin of Controlled Biology
Biomedical R&D begins in allograft tissue processing and regulated medical-device systems, establishing a foundational focus on achieving biological safety without compromising functional integrity.
1999
Precision Delivery as a System
First cannula-based delivery system developed for minimally invasive spinal fusion, marking the shift from isolated components to fully integrated procedural systems.
2001
Translation into Clinical Reality
Multiple allograft implant technologies invented and commercialized, including bone void fillers and spinal fusion devices validated through real-world clinical use.
2006
Sterilization Without Radiation
Development of T10⁶®, the first non-irradiated supercritical CO₂ sterilization process for allograft tissue, demonstrating that sterility and biological performance can coexist.
2010
SteriFlex® Is Formalized
Introduction of the SteriFlex® platform: customizable vapor-phase hydrogen peroxide (VHP) terminal sterilization, resulting in the first non-irradiated tissue products approved for clinical use in the United States and Canada.
2015
The Principle Becomes Universal
Patent of TheBOX®, a Reactive Oxygen™® sterilization and infusion system, extending PuroGen's regulation-first, integrity-preserving principles beyond medicine into new biological domains.
2024
The Standard Catches Up
FDA reclassifies VHP from Category B (novel) to Category A (established) sterilization method. ISO 22441 published as the international consensus standard. The regulatory framework PuroGen anticipated for two decades is now formally recognized.
Present
Custom VHP Systems for Device Manufacturers
PuroGen engineers custom VHP sterilization systems for medical device companies bringing sterilization in-house. The convergence of Category A recognition, ISO 22441 validation pathways, and three decades of PuroGen engineering makes adoption practical — not experimental.
"What we build today must remain valid tomorrow — through regulatory evolution, industry maturation, and the steadily increasing demand for certainty in controlled environments."
Industries We Serve
Allograft Tissue Processing
Medical Device Sterilization
Pharmaceutical Manufacturing
Semiconductor Fabrication
Biotechnology Research
Seed & Crop Genetics
We build what must work.
Learn more about our platforms or get in touch.